Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | SVP, CHIEF ACCOUNTING OFFICER | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,199 |
Ending reported balance
After 2026-06-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-17 · Exercise / conversion · Acquired 19,686 · Balance 89,885 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. Row 2 · 2026-06-17 · Sale · Disposed 19,686 · Balance 70,199 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.69 · Expires 2034-02-14 | Direct | 15,314 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Exercise / conversion · Disposed 19,686 · Balance 15,314 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. F2: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026.
F2: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 703 | $18.01 Strike: $18.01 | $12,661.03 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · derivative · entry 15 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,297 Underlying: Common Stock · 703 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. F5 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 49 | $30.86 Strike: $30.86 | $1,512.14 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · derivative · entry 14 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,951 Underlying: Common Stock · 49 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. F4 · derivative.exercise_date: This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 236 | $27.05 Strike: $27.05 | $6,383.80 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · derivative · entry 13 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,133 Underlying: Common Stock · 236 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 703 | $45.00 | $31,635.00 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 6 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 703 | $18.01 | $12,661.03 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 5 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 49 | $45.00 | $2,205.00 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 4 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 49 | $30.86 | $1,512.14 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 236 | $45.00 | $10,620.00 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 01:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 236 | $27.05 | $6,383.80 |
DisclosureSEC source: 0001070081-19-000042 · wf-form4_156211801686164.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 9, 2018. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 6,300 | $11.23 Strike: $11.23 | $70,749.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · derivative · entry 14 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Underlying: Common Stock · 6,300 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F11 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 18,750 | $13.10 Strike: $13.10 | $245,625.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · derivative · entry 13 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 18,750 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F10 · derivative.exercise_date: This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,150 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · derivative · entry 12 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,150 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,540 | $35.17 | $124,501.80 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 11 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.44 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,760 | $34.70 | $95,772.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 10 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,477 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.94 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,300 | $11.23 | $70,749.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 9 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,821 | $35.21 | $310,587.41 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 8 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.71 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,929 | $34.75 | $345,032.75 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 7 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,758 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.06 to $34.99 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 18,750 | $13.10 | $245,625.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 6 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 610 | $35.17 | $21,453.70 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 5 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.40 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 540 | $34.71 | $18,743.40 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 4 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,547 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.94 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,150 | $10.85 | $12,477.50 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 3 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $35.25 | $35,250.00 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 2 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.60 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:31 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,509 | $34.78 | $52,483.02 |
DisclosureSEC source: 0001070081-19-000020 · wf-form4_155201228629693.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,937 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.98 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:53 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,100 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003208 · a4.xml · derivative · entry 2 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Stock · 10,100 shares Expires 2029-01-21 F2 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 22:53 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001104659-19-003208 · a4.xml · derivative · entry 1 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 22:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 297 | $34.75 | $10,320.75 |
DisclosureSEC source: 0001070081-19-000010 · wf-form4_154707186908284.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,446 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 975 RSUs from a January 3, 2017 grant of 3,900 RSUs. F2 · balance_after: Includes 715 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2018 and 368 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2018. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 21:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 412 | $17.67 | $7,280.04 |
DisclosureSEC source: 0001070081-18-000016 · wf-form4_151518641813910.xml · nonDerivative · entry 1 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,660 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 975 RSUs from a January 3, 2017 grant of 3,900 shares. F2 · balance_after: Includes 1,112 shares acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2017 and 663 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2017. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 40,000 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001070081-18-000016 · wf-form4_151518641813910.xml · derivative · entry 2 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 22:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 25,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001070081-17-000102 · wf-form4_149678789686726.xml · derivative · entry 2 Utter Christine Marie · CIK 0001707685 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-02 F1 · derivative.exercise_date: This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.